Log In
BCIQ
Print this Print this
 

BGM Galectin-3 test (automated)

  Manage Alerts
Collapse Summary General Information
Company BG Medicine Inc.
DescriptionBlood-based test to measure galectin-3, a soluble beta-galactoside-binding lectin associated with the formation of cardiac fibrosis, in human plasma or serum
Molecular Target Galectin-3 (LGALS3)
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCardiovascular, Diagnostic
Indication DetailsAid in assessing the prognosis of patients with heart failure
Regulatory Designation
PartnerAbbott Laboratories;
Alere Inc.;
bioMerieux S.A.;
Siemens AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$8,400.0M

$5,800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/01/2016

$8,400.0M

$5,800.0M

0

03/15/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today